Table 3 Variations existing in the efficacy of certain novel biologics

 − 1.04 (− 4.76, 2.68)

Zilucoplan

 − 1.49 (− 4.83, 1.85)

 − 0.45 (− 4.00, 3.10)

Eculizumab

 − 1.88 (− 5.22, 1.46)

 − 0.84 (− 4.40, 2.71)

 − 0.39 (− 3.54, 2.76)

Rozanolixizumab

 − 1.59 (− 4.63, 1.45)

 − 0.55 (− 3.82, 2.72)

 − 0.10 (− 2.93, 2.73)

0.29 (− 2.54, 3.13)

Ravulizumab

 − 2.34 (− 5.39, 0.71)

 − 1.30 (− 4.58, 1.98)

 − 0.85 (− 3.69, 1.99)

 − 0.46 (− 3.30, 2.38)

 − 0.75 (− 3.23, 1.73)

Rituximab

 − 2.42 (− 5.52, 0.67)

 − 1.38 (− 4.71, 1.94)

 − 0.93 (− 3.82, 1.95)

 − 0.54 (− 3.43, 2.35)

 − 0.83 (− 3.37, 1.70)

 − 0.08 (− 2.63, 2.46)

Efgartigimod

 − 4.05 (− 6.89, − 1.22)

 − 3.01 (− 6.10, 0.07)

 − 2.56 (− 5.17, 0.05)

 − 2.17 (− 4.78, 0.44)

 − 2.46 (− 4.68, − 0.25)

 − 1.71 (− 3.94, 0.52)

 − 1.63 (− 3.91, 0.65)

Batoclimab

 − 3.29 (− 5.78, − 0.80)

 − 2.25 (− 5.02, 0.52)

 − 1.80 (− 4.03, 0.43)

 − 1.41 (− 3.64, 0.82)

 − 1.70 (− 3.45, 0.05)

 − 0.95 (− 2.71, 0.82)

 − 0.87 (− 2.70, 0.97)

0.76 (− 0.60, 2.12)

Placebo